Please select the option that best describes you:
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
Which patients, if any, do you screen with ctDNA-based assays?
What management strategies do you discuss with patients who are MRD-positive?
Answer from: Medical Oncologist at Academic Institution
I do not, as part of the standard of care, in part because of limitations of the ClonoSeq assay in this setting, and in part because of a lack of clarity around how best to manage a positive. However, there are a number of sophisticated clinical trials exploring this question prospectively, with a f...
Sign In or Register to read more